Myovant Sciences launched in June 2016. Four months later it rallied the largest biotech IPO of the year, raising $218 million on the New York Stock Exchange.
On Thursday, the women’s health company continued its sprint-to-market, launching tw0 international Phase 3 trials — the first of five planned this year — to evaluate the safety and efficacy of its lead compound, relugolix, in women with uterine fibroids.
That’s a productive 6-7 months.
